医学
曲妥珠单抗
内科学
伊立替康
肿瘤科
结直肠癌
临床终点
克拉斯
帕妥珠单抗
癌症
中性粒细胞减少症
乳腺癌
化疗
临床试验
作者
Ting Xu,Xicheng Wang,Ying Xin,Zhenghang Wang,Jifang Gong,Xiaotian Zhang,Yanyan Li,Congcong Ji,Yu Sun,Feilong Zhao,Depei Huang,Yuezong Bai,Jian Li,Lin Shen
标识
DOI:10.4143/crt.2022.1058
摘要
The human epidermal growth factor receptor 2 (HER2) is an established therapeutic target for various kinds of solid tumors. HER2 amplification occurs in approximately 1% to 6% of colorectal cancer. In this study, we aimed to assess the efficacy and safety of trastuzumab in combination with chemotherapy in HER2-positive mCRC.An open-label, phase II trial (Clinicaltrials.gov: NCT03185988) was designed to evaluate the antitumor activity of trastuzumab and chemotherapy in HER2-positive digestive cancers excluding gastric cancer in 2017. Patients from this trial with HER2-positive, KRAS/BRAF wild-type, unresectable mCRC were analyzed in this manuscript. Eligible patients were treated with trastuzumab (8 mg/kg loading dose and then 6 mg/kg q3w) and irinotecan (120 mg/m2 d1,8 q3w). The primary endpoint was the objective response rate (ORR).Twenty-one HER2-positive mCRC patients were enrolled in this study. Seven (33.3%) patients achieved an objective response, and 11 (52.4%) patients had stable disease as their best response. The median progression-free survival (PFS) was 4.3 months (95% CI: 2.7 - 5.9 m). Four (19.0%) of the 21 patients had Grade 3 adverse events, including leukopenia, neutropenia, urinary tract infection, and diarrhea. No treatment-related death was reported. Exploratory analyses revealed that high tumor tissue HER2 copy number was associated with better therapeutic response and PFS. Alterations in the MAPK pathway, HER2 gene, PI3k/AKT pathway, and cell cycle control genes were potential drivers of trastuzumab resistance in mCRC.Trastuzumab combined with chemotherapy is a potentially effective and well-tolerated therapeutic regimen in mCRC with a high HER2 copy number.
科研通智能强力驱动
Strongly Powered by AbleSci AI